Examination of autoantibodies to type I interferon in patients suffering from long COVID
Journal of Medical Virology · 2023-09 · 95 (9)
DOI: 10.1002/jmv.29089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 12.09.2023. Verfasst von Kristoffer Skaalum Hansen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: COVID-19, Interferon Type I. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lundbeckfonden, Danmarks Frie Forskningsfond, Novo Nordisk Fonden.
Abstract (Originalsprache)
Long COVID (LC) is an emerging global health concern. The underlying mechanism and pathophysiology remain unclear. Presence of neutralizing autoantibodies against type 1 interferons (IFN) has been established as a predictor of critical COVID‐19. We hypothesized that persistent autoimmune activity with autoantibodies against type 1 IFN may contribute to symptoms in patients with LC. Plasma samples and clinical information were obtained from a Danish LC cohort consisting of adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Information on symptoms and quality of life was derived from an LC‐specific questionnaire and the EQ‐5D‐5L questionnaire. Detection of type 1 IFN autoantibodies in plasma were performed by ELISA. Samples collected between June, 2020, and September, 2021, from 279 patients were analyzed and compared to a control group of 94 individuals with prior mild SARS‐CoV‐2 infection who did not develop LC symptoms. In total, five LC patients (1.8%) and 3 (3.2%) of the controls had detectable circulating type 1 IFN autoantibodies. Collectively, prevalence of autoantibodies against type 1 IFN subtypes in our LC cohort were primarily driven by men and did not exceed the prevalence in controls. Thus, in our cohort, anti‐type I IFN autoantibodies are unlikely to drive LC symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Biomedicine, Aarhus University, Aarhus, Denmark.
- Research Unit of General Practice, University of Southern Denmark, Odense, Denmark.
- Department of Infectious Diseases & Internal Medicine, Gødstrup Regional Hospital, Herning, Denmark.
ORCID-Profile: Kristoffer Skaalum Hansen, Morten Kelder Skouboe
Förderung
- Lundbeckfonden
- Danmarks Frie Forskningsfond
- Novo Nordisk Fonden
Zitieren
APA
Hansen, K. S., Jørgensen, S. E., Skouboe, M. K., Agergaard, J., Schiøttz-Christensen, B., Vibholm, L. K., Tolstrup, M., Østergaard, L., Leth, S., & Mogensen, T. H. (2023). Examination of autoantibodies to type I interferon in patients suffering from long COVID. Journal of Medical Virology, 95(9). https://doi.org/10.1002/jmv.29089
Vancouver
Hansen KS, Jørgensen SE, Skouboe MK, Agergaard J, Schiøttz-Christensen B, Vibholm LK, et al. Examination of autoantibodies to type I interferon in patients suffering from long COVID. Journal of Medical Virology. 2023;95(9). doi:10.1002/jmv.29089
BibTeX
@article{Hansen2023,
author = {Hansen, Kristoffer Skaalum and Jørgensen, Sofie Eg and Skouboe, Morten Kelder and Agergaard, Jane and Schiøttz-Christensen, Berit and Vibholm, Line Khalidan and Tolstrup, Martin and Østergaard, Lars and Leth, Steffen and Mogensen, Trine H},
title = {Examination of autoantibodies to type I interferon in patients suffering from long COVID},
journal = {Journal of Medical Virology},
year = {2023},
volume = {95},
number = {9},
doi = {10.1002/jmv.29089}
}
EUVIMED